. 2020 Nov 5;39(3):317–330. doi: 10.1007/s40273-020-00967-7

Table 5.

Budget-impact model results per patient: 5 years

Time point	Oral semaglutide 14 mg							Sitagliptin 100 mg
	HbA1c	Survival (%)	Diabetes therapy cost	CVD cost	Hypoglycemia cost	Other direct medical costs^b	Total costs	HbA1c	Survival (%)	Diabetes therapy cost	CVD cost	Hypoglycemia cost	Other direct medical costs^b	Total costs
Baseline	8.33	100.0						8.33	100.0
Year 1	7.03	99.0	6051	544	23	409	7037	7.53	99.0	1571	569	40	424	2604
Year 2	7.45	97.9	5986	586	22	391	6985	7.83	97.9	1554	601	39	411	2605
Year 3	7.79	96.7	5906	628	23	427	6984	8.08	96.6	1533	645	38	452	2668
Year 4	8.06	95.4	5837	646	23	469	6975	6.20^a	95.4	6709	628	30	430	7797
Year 5	6.76^a	94.0	10,866	664	29	458	12,017	6.87	94.0	6616	664	31	451	7762
Years 1–5			34,645	3078	120	2154	39,997			17,983	3107	178	2168	23,436
Difference between oral semaglutide vs. sitagliptin—years 1–5										16,663	− 29	− 58	− 14	16,562
% difference										92.7	− 0.9	− 32.6	− 0.7	70.7

Costs are presented as $US, year 2019 values

CVD cardiovascular disease, HbA1c glycated hemoglobin

^aTreatment switch = metformin + primary therapy + insulin glargine

^bOther direct medical costs include management, renal, ulcer/amputation/neuropathy, eye